Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
← catalyst calendarNCT07222800 · readout in 1,318 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
800estimated
Sites
308
Countries
Argentina, Australia, Belgium +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-11 | actual | When the study began enrolling |
| Primary completion | 2030-03-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-08-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Intestinal Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Neoplasms by Site
- Digestive System Diseases
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Rectal Diseases
- Colorectal Neoplasms
Interventions
- Drug: PF-08634404
- Biological: Bevacizumab — also filed as Avastin
- Drug: Chemotherapy
Primary outcomes
what the primary-completion date above is the date OFProgression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)
measured Approximately 4 years
Overall survival (OS)
measured Approximately 4 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed